MENU
THNR
ETF ticker: NYSE ARCA
PRICE
CHANGE
NET ASSETS

THNR stock forecast, quote, news & analysis

The investment seeks investment results that generally correspond to the performance of the VettaFi Weight Loss Drug & Treatment Index... Show more

Category: #Health
THNR
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for THNR with price predictions
Sep 11, 2026

THNR's RSI Indicator leaves overbought zone

The 10-day RSI Oscillator for THNR moved out of overbought territory on August 26, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 11 instances where the indicator moved out of the overbought zone. In 11 of the 11 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on THNR as a result. In 29 of 37 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.

The Moving Average Convergence Divergence Histogram (MACD) for THNR turned negative on August 31, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 22 similar instances when the indicator turned negative. In 20 of the 22 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

THNR moved below its 50-day moving average on September 09, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where THNR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +1.84% 3-day Advance, the price is estimated to grow further. Considering data from situations where THNR advanced for three days, in 105 of 124 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

THNR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 82 of 92 cases where THNR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 89%.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Merck & Co (NYSE:MRK), AstraZeneca PLC (NYSE:AZN), Amgen (NASDAQ:AMGN), Pfizer (NYSE:PFE), Teva Pharmaceutical Industries Limited (NYSE:TEVA).

Industry description

The investment seeks investment results that generally correspond to the performance of the VettaFi Weight Loss Drug & Treatment Index. The fund's manager invests at least 80% of its net assets (plus borrowings for investment purposes) in securities that comprise the index. The index is comprised of global companies expected to economically benefit from weight loss drug development. The index includes pharmaceutical manufacturers, manufacturers of combination therapies and telehealth providers who provide access to Amylin agonists and analogs or GLP-1 agonists and analogs, including dual GLP-1 agonists and analogs. The fund is non-diversified.

Market Cap

The average market capitalization across the Amplify Weight Loss Drug & Treatment ETF ETF is 164.34B. The market cap for tickers in the group ranges from 634.52M to 994.49B. LLY holds the highest valuation in this group at 994.49B. The lowest valued company is ALT at 634.52M.

High and low price notable news

The average weekly price growth across all stocks in the Amplify Weight Loss Drug & Treatment ETF ETF was -5%. For the same ETF, the average monthly price growth was -3%, and the average quarterly price growth was 5%. ROG experienced the highest price growth at 7%, while GPCR experienced the biggest fall at -18%.

Volume

The average weekly volume growth across all stocks in the Amplify Weight Loss Drug & Treatment ETF ETF was 10%. For the same stocks of the ETF, the average monthly volume growth was -25% and the average quarterly volume growth was -43%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 40
P/E Growth Rating: 54
Price Growth Rating: 44
SMR Rating: 66
Profit Risk Rating: 68
Seasonality Score: -7 (-100 ... +100)
View a ticker or compare two or three
THNR
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Details
Category
Health
Address
Amplify ETF Trust3250 Lacey Road, Suite 130Downers Grove
Phone
(630) 464-7600
Web
N/A
THNR's RSI Indicator leaves overbought zone